Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 9:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 5mg Olanzapine Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery

NCT00699946
View directory record Official record
Conditions
Delirium
Interventions
olanzapine, placebo
Drug
Lead sponsor
The New England Baptist Hospital
Other
Eligibility
65 Years and older
Enrollment
495 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 22, 2026, 9:16 PM EDT
Completed No phase listed Observational

Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation

NCT03211897
View directory record Official record
Conditions
Agitation,Psychomotor
Interventions
Haloperidol Injection, Ziprasidone Injection, OLANZapine Injection, Midazolam injection
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
737 participants
Timeline
2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg

NCT00647777
View directory record Official record
Conditions
Healthy
Interventions
Olanzapine Tablets 5 mg, Zyprexa® Tablets 5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg

NCT00648921
View directory record Official record
Conditions
Healthy
Interventions
Olanzapine Tablets 5 mg, Zyprexa® Tablets 5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 22, 2026, 9:16 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

NCT04216329
View directory record Official record
Conditions
Gliosarcoma, Newly Diagnosed, Glioblastoma
Interventions
Selinexor, Temozolomide, Generic Radiation therapy (RT), Selective serotonin receptor (5-HT3) antagonists, Olanzapine, Salt tablets, Anti-diarrheal
Drug · Radiation · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo

NCT01920802
View directory record Official record
Conditions
Healthy
Interventions
olanzapine, iloperidone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 35 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery

NCT05676294
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metabolic Effects of Olanzapine in Healthy Males

NCT01496183
View directory record Official record
Conditions
Healthy
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Results available

Sustaining Remission of Psychotic Depression

NCT01427608
View directory record Official record
Conditions
Psychotic Depression
Interventions
Sertraline + Olanzapine, Sertraline + Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 85 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Worcester, Massachusetts • White Plains, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants

NCT04535141
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Olanzapine 5 MG, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 1 Interventional Results available

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

NCT06319170
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine Extended Release, Olanzapine Immediate Release
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Los Alamitos, California • Hollywood, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder

NCT04987658
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
OLZ/SAM
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
10 Years to 12 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Decatur, Georgia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

A New Pharmacotherapy for Alcohol Dependence: Olanzapine

NCT00746785
View directory record Official record
Conditions
Alcohol Dependence
Interventions
2.5 mg Olanzapine, 5mg Olanzapine, placebo
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
21 Years to 55 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PET Imaging and Olanzapine Treatment in Borderline Personality Disorder

NCT00275301
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
olanzapine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Olanzapine for Acute Headaches

NCT03066622
View directory record Official record
Conditions
Headache
Interventions
Standard of Care as per attending physician, 5mg rapidly dissolving olanzapine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan

NCT05547100
View directory record Official record
Conditions
Focus of Study is on Healthy Lactating Women
Interventions
LYBALVI
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Results available

Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)

NCT00303602
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Sublingual orally disintegrating olanzapine (SODO), Oral olanzapine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Escondido, California • Garden Grove, California • National City, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2009 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy

NCT02097823
View directory record Official record
Conditions
Chemotherapy Induced Nausea and Vomiting
Interventions
Olanzapine, Aprepitant
Drug
Lead sponsor
Indiana University
Other
Eligibility
4 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 22, 2026, 9:16 PM EDT
Completed Phase 4 Interventional Results available

Short Term Rescue Study of Olanzapine

NCT00186017
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Olanzapine/Zyprexa
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 22, 2026, 9:16 PM EDT